Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.alembiclimited.com | |
Market Cap | 1,829.57 Cr. | |
Enterprise Value(EV) | 1,803.34 Cr. | 2022-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 8.65 | Trailing Twelve Months Ending 2022-03 |
Price-Earning Ratio (PE) | 8.24 | Trailing Twelve Months Ending 2022-03 |
Industry PE | 28.47 | Trailing Twelve Months Ending 2022-03 |
Book Value / Share | 75.82 | Trailing Twelve Months Ending 2022-03 |
Price to Book Value | 0.93 | Calculated using Price: 70.20 |
Dividend Yield | 2.53 | Period Ending 2021-03 |
No. of Shares Subscribed | 25.68 Cr. | 256,781,828 Shares |
FaceValue | 2 | |
Company Profile | ||
Alembic was incorporated in 1907 as Alembic Chemical Works Company, primarily engaged in production of tinctures and alcohol at Baroda. Later the company set up distillery plant for pharmaceutical purposes at Baroda. It started manufacturing of cough syrup, vitamins, tonics and sulphur drugs. In 1952, the company set up its research and development activity. Currently the company has developed research activity in area of chemistry, microbiology, pharmaceutical technology and bio-equivalence. The company’s manufacturing units are located in Baroda and Baddi. Company’s plant has received various certifications such as ISO-9002, ISO-14001 and ISO 27001 and also follows WHO-GMP guidelines. The company has presence in 75 countries globally. Business area APIs- The Company is engaged in manufacturing of active pharmaceutical ingredients for anti-parkinsons, anti-depressants, cephalosporins, macrolides and others. Bulk Pharmaceuticals- Under this the company manufactures bulk drugs that are phosgene based and intermediates. Formulation- The company manufactures around 150 products under this segment in therapeutic areas such as anti-infective, cough and cold products to cardiovascular and oral anti-diabetics. Herbal and Nutraceuticals- The company manufactures herbal and Nutraceuticals and has created brands like Isovon, Protinules, ALA-100, Diax and many more. Alembic also provides contract research services in area of chemistry, bioequivalence and bioanalytical. It also manufactures products for animal care such as Antibiotics-injections, Analgesics, Antipyretics, antidiarrhoeals, Vitamins-Oral and injectable, Tonics and Nutritional feed supplements. Outlook The company has acquired API manufacturing unit of Nirayu that is located at Gujarat at a consideration of Rs 17.50 Crores. |
1 Day |
|
+0.71% |
1 Week |
|
+3.29% |
1 Month |
|
-12.63% |
3 Month |
|
-23.15% |
6 Month |
|
-33.03% |
1 Year |
|
-46.59% |
2 Year |
|
+36.20% |
5 Year |
|
+58.18% |
10 Year |
|
+818.62% |
9 years | 2009-03 | 2010-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | 3.22 | 11.83 | 5.58 | 3.71 | 3.21 | 4.18 | 3.58 | 7.08 | 0.75 | |
Return on Capital Employed (%) | 7.79 | 10.54 | 3.82 | 3.82 | 3.12 | 4.44 | 3.91 | 7.12 | 0.94 | |
Return on Assets (%) | 1.08 | 3.82 | 2.88 | 3.25 | 2.94 | 3.88 | 3.39 | 6.80 | 0.71 |
Particulars | 8 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
Shh. Funds | 528 | 803 | 911 | 1,086 | 1,209 | 1,418 | 2,297 | 2,497 | |
Non Curr. Liab. | 38 | 15 | 13 | 14 | 9 | 7 | 53 | 68 | |
Curr. Liab. | 82 | 58 | 68 | 59 | 49 | 46 | 59 | 68 | |
Minority Int. | |||||||||
Equity & Liab. | 648 | 876 | 992 | 1,159 | 1,266 | 1,471 | 2,409 | 2,632 | |
Non Curr. Assets | 458 | 706 | 801 | 972 | 1,167 | 1,308 | 2,307 | 2,489 | |
Curr. Assets | 189 | 169 | 191 | 187 | 99 | 163 | 102 | 143 | |
Misc. Exp. not W/O | |||||||||
Total Assets | 648 | 876 | 992 | 1,159 | 1,266 | 1,471 | 2,409 | 2,632 |
Particulars | 8 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
Net Sales | 144 | 128 | 147 | 125 | 124 | 74 | 74 | 78 | |
Other Income | 22 | 29 | 31 | 37 | 29 | 94 | 11 | 90 | |
Total Income | 166 | 156 | 178 | 162 | 153 | 167 | 84 | 167 | |
Total Expenditure | -135 | -122 | -140 | -114 | -106 | -71 | -63 | -64 | |
PBIDT | 30 | 35 | 38 | 48 | 48 | 97 | 21 | 103 | |
Interest | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Depreciation | -6 | -6 | -5 | -4 | -3 | -3 | -4 | -5 | |
Taxation | 1 | -1 | 1 | -2 | -4 | 0 | -3 | -12 | |
Exceptional Items | -3 | -6 | |||||||
PAT | 24 | 25 | 27 | 42 | 41 | 93 | 14 | 86 | |
Minority Interest | |||||||||
Share Associate | 82 | 210 | 118 | 121 | 172 | 236 | 329 | 136 | |
Other Related Items | |||||||||
Consolidated Net Profit | 107 | 235 | 145 | 163 | 213 | 329 | 343 | 222 | |
Adjusted EPS | 4 | 9 | 5 | 6 | 8 | 13 | 13 | 9 |
Particulars | 7 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | 22 | 10 | 52 | 24 | 22 | 7 | -2 | |
Cash Fr. Inv. | 5 | -5 | -47 | -22 | 72 | 57 | -35 | |
Cash Fr. Finan. | -25 | -5 | -5 | -3 | -92 | -6 | -15 | |
Net Change | 2 | 0 | 0 | -1 | 1 | 57 | -52 | |
Cash & Cash Eqvt | 3 | 2 | 2 | 1 | 2 | 59 | 7 |
Thu, 19 May 2022
Loss of share certificate
|
|
Thu, 19 May 2022
Related Party Transaction
|
|
Wed, 18 May 2022
Related Party Transaction
|
Thu, 19 May 2022 |
|
|
|
|
|